Revlimid(Lenalidomide) in Dano Health view
Lenalidomide with the trade name Revlimid is imitative of thalidomide which was introduced in 2004 and developed by modification of the structural backbone of thalidomide.
It was intended as a treatment for multiple myeloma at first while thalidomide is an accepted therapeutic treatment for it. Lenalidomide along with some new drugs developed recently has significantly improved overall survival in myeloma although toxicity issue remains as a problem for the users of this drug. Lenalidomide has also shown some efficacy in the class of hematological disorders known as Myelodysplastic Syndromes (MDS).
In 2006: FDA approved Lenalidomide, an orally administered thalidomide analog, for use with dexamethasone in patients with Multiple Myeloma. Also, it should be noted that these patients received at least one prior therapy.
In 2013: Lenalidomide was approved by the FDA as the treatment of patients with Mantle Cell Lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib.
In 2015: the indication was expanded for the treatment of patients with multiple myeloma and include newly diagnosed multiple myeloma patients, ineligible for autologous stem cell transplant. It is also received approval for myelodysplastic syndromes and mantle cell lymphoma.
In 2017: Lenalidomide was approved by the U.S. Food and Drug Administration as maintenance therapy for patients with multiple myeloma following autologous Hematopoietic Stem Cell Transplant (auto-HSCT).
- Mantle Cell Lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included Bortezomib.
Lenalidomide may be used as part of clinical trials for other types of cancer. For myeloma, it will be used with a steroid drug called Dexamethasone or with a chemotherapy called Melphalan and dexamethasone. It is also being investigated for treating chronic lymphocytic leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and solid tumor cancers such as carcinoma of the pancreas.
Mechanism of Lenalidomide is not yet completely understood and researchers are still working on its mechanism. Lenalidomide
- stops multiplying of cancerous plasma cells
- (Immunomodulatory properties of lenalidomide) enhances the action of natural killer cells (cells in the immune system) and T cells; These cells naturally attack abnormal cells like cancerous cells.
- stops tumors making their own new blood vessels that are essential for their living and provide them with nutrients and oxygen.
Multiple Myeloma (MM) is a neoplastic disorder; During this disease, clonal plasma cells accumulated in the bone marrow and represents 10% of hematological malignancies, and neuropathy. Lenalidomide has dual effects on MM; it directs both tumoricidal properties and immunomodulatory activity so that control MM rapidly and sustainably.
Multiple Myeloma(MM) treatments are:
- chemotherapy and other drugs biologic therapy
- stem-cell transplant (SCT)
In drug therapy, Celgene as the main Revlimid seller dominates the MM market in the U.S. This drug included in all lines of MM therapy either as monotherapy or in combination with other drugs in the U.S. The RD (Revlimid and dexamethasone) and RVD (Revlimid, Velcade (Bortezomib, Takeda), and Dexamethasone combinations are the most commonly used regimens for newly diagnosed patients who are eligible for SCT and also for newly diagnosed, SCT-ineligible patients.
Revlimid price is about $20,338 for a pack of 28 capsules, depending on the pharmacy you visit. In the following table, you can see different treatments price.
|Drug Manufacturer||Description||Cost of 24 Weeks of Treatment|
|Anti-CD38 monoclonal antibody||M: $123,034d
|Anti-CS1 monoclonal antibody||M: $101,161d
|Thalidomide analog with antiangiogenic and anti-neoplastic properties||$76,007|
|Thalidomide analog with antineoplastic activity||$88,032|
|An immunomodulatory agent with anti-inflammatory and anti-angiogenic properties||$63,673|
MM after lymphoma and leukemia is the third most common blood cancer in the U.S. Men and African-Americans have a higher incidence than women and whites. In 2014, it was reported that more than 24,000 people would be diagnosed with MM in the U.S. and that more than 11,000 would die from it.
The international market of Lenalidomide will be developed because of progress and inventions comprising economic study and provincial improvement. All Revlimid distributors and also Turkish pharmaceutical sellers will see a significant improvement in this market.
Lenalidomide Market’s division is:
- The division based on the Type of Product; with reference to manufacturing, profits, price, and market segment and development percentage for each type.
- The division based on the Type of Use; for treating Multiple Myeloma, and Myelodysplastic Syndromes.
Some of the most important active Revlimid sellers are Celegene, Ablynx, Natco Pharma, Celltrion, Dexa Medica, LEO Pharma, Toyama Chemical, Sanofi, GlaxoSmithKline, Han All Biopharma, Shanghai CP Guojian Pharmaceutical, and Tsumura. Dano Health as a clinical trial product distributor can provide Revlimid for the companies who looking for it.